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Outcomes in pediatric studies of medium-
chain acyl-coA dehydrogenase (MCAD)
deficiency and phenylketonuria (PKU): a
review
Michael Pugliese1, Kylie Tingley1, Andrea Chow1, Nicole Pallone2, Maureen Smith3, Alvi Rahman1,
Pranesh Chakraborty4, Michael T. Geraghty5, Julie Irwin6, Laure Tessier4, Stuart G. Nicholls7, Martin Offringa8,9,
Nancy J. Butcher9, Ryan Iverson1, Tammy J. Clifford1, Sylvia Stockler10, Brian Hutton1, Karen Paik1, Jessica Tao11,
Becky Skidmore7, Doug Coyle1, Kathleen Duddy10, Sarah Dyack12, Cheryl R. Greenberg13, Shailly Jain Ghai14,
Natalya Karp15, Lawrence Korngut16, Jonathan Kronick8,17, Alex MacKenzie18, Jennifer MacKenzie19,
Bruno Maranda20, John J. Mitchell21, Murray Potter22, Chitra Prasad15, Andreas Schulze8, Rebecca Sparkes23,
Monica Taljaard1,7, Yannis Trakadis24, Jagdeep Walia25, Beth K. Potter1* and Canadian Inherited Metabolic
Diseases Research Network
Abstract
Background: Inherited metabolic diseases (IMDs) are a group of individually rare single-gene diseases. For many
IMDs, there is a paucity of high-quality evidence that evaluates the effectiveness of clinical interventions. Clinical
effectiveness trials of IMD interventions could be supported through the development of core outcome sets (COSs),
a recommended minimum set of standardized, high-quality outcomes and associated outcome measurement
instruments to be incorporated by all trials in an area of study. We began the process of establishing pediatric COSs
for two IMDs, medium-chain acyl-CoA dehydrogenase (MCAD) deficiency and phenylketonuria (PKU), by reviewing
published literature to describe outcomes reported by authors, identify heterogeneity in outcomes across studies,
and assemble a candidate list of outcomes.
Methods: We used a comprehensive search strategy to identify primary studies and guidelines relevant to children
with MCAD deficiency and PKU, extracting study characteristics and outcome information from eligible studies
including outcome measurement instruments for select outcomes. Informed by an established framework and a
previously published pediatric COS, outcomes were grouped into five, mutually-exclusive, a priori core areas:
growth and development, life impact, pathophysiological manifestations, resource use, and death.
(Continued on next page)
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Results: For MCAD deficiency, we identified 83 outcomes from 52 articles. The most frequently represented core
area was pathophysiological manifestations, with 33 outcomes reported in 29/52 articles (56%). Death was the most
frequently reported outcome. One-third of outcomes were reported by a single study. The most diversely measured
outcome was cognition and intelligence/IQ for which eight unique measurement instruments were reported
among 14 articles. For PKU, we identified 97 outcomes from 343 articles. The most frequently represented core area
was pathophysiological manifestations with 31 outcomes reported in 281/343 articles (82%). Phenylalanine
concentration was the most frequently reported outcome. Sixteen percent of outcomes were reported by a single
study. Similar to MCAD deficiency, the most diversely measured PKU outcome was cognition and intelligence/IQ
with 39 different instruments reported among 82 articles.
Conclusions: Heterogeneity of reported outcomes and outcome measurement instruments across published
studies for both MCAD deficiency and PKU highlights the need for COSs for these diseases, to promote the use of
meaningful outcomes and facilitate comparisons across studies.
Keywords: PKU, MCAD deficiency, Core outcome sets, Rare diseases, Patient-oriented outcomes
Background
Inherited metabolic diseases (IMD) are a large group of
single-gene diseases that are individually rare but when
aggregated have an estimated global birth prevalence of
50.9 in 100,000 live births [1]. These diseases are typic-
ally diagnosed early in life, often involve complex and
resource-intensive medical care [2], and are frequently
associated with intense home management and caregiv-
ing needs [3]. Providing effective treatment can be diffi-
cult due to a scarcity of evidence supporting current
therapies [4]. When properly conducted, randomized
controlled trials are considered the ‘gold standard’ pri-
mary study design for evaluating interventions [5]. How-
ever, trials have not always focused on those outcomes
that are most relevant to patients diagnosed with the
diseases being studied [6], and different trials within a
single area of research have often incorporated disparate
outcomes and outcome measurement instruments, thus
impeding comparisons among studies and limiting cap-
acity for data synthesis [7]. In response to these chal-
lenges, the Core Outcome Measures in Effectiveness
Trials (COMET) Initiative [8] has led researchers in
many disease areas to develop core outcome sets (COSs)
[7]. A COS is a recommended minimum set of standard-
ized, high-quality outcomes and associated outcome
measurement instruments to be incorporated by all trials
in an area of study [7]. COSs are developed to be rele-
vant to all stakeholders in an area of research, including
patients and their families, health care providers, and
health policy decision-makers. Development and uptake
of COSs aim to ensure that results can be synthesized
and compared across studies.
It may be particularly valuable to develop COSs for
IMDs and other rare diseases. Trials are less common
and more challenging to implement for rare diseases
relative to common diseases in part due to the difficul-
ties in assembling a large enough cohort of patients to
obtain adequate statistical power [9, 10]. Consequently,
there may be great interest in comparing and synthesiz-
ing the results of all trials of one or more interventions
for a rare disease (for example, using systematic reviews
and meta-analyses) when considering evidence to sup-
port treatment and policy decisions. Consistent selection
of outcomes and outcome measurement instruments
across effectiveness trials would facilitate such evidence
synthesis and make best use of the limited resources that
are available for rigorous evaluative research for rare dis-
eases. This is especially important for IMDs given the
current rapid pace of development of new therapies [11],
which has resulted in an increasing need for timely evi-
dence regarding the effectiveness and comparative ef-
fectiveness of emerging and existing treatments. Given
that clinical trial outcomes can determine the evidence
considered by patients, clinicians, and policy advisors
when making patient care and health policy decisions,
the outcomes measured in future trials of interventions
for IMDs should be carefully considered.
In the present study we sought to comprehensively re-
view outcomes reported in previously published
pediatric studies related to two of the most common
IMDs, medium-chain acyl-coA dehydrogenase (MCAD)
deficiency and phenylketonuria (PKU). For both MCAD
deficiency and PKU, there are no existing COSs, limited
evidence is available regarding new treatments, and there
is a scarcity of trials reporting patient-oriented outcomes
[12–16]. Our specific aims were to: (i) identify the
unique outcomes that have been reported or recom-
mended in the literature for these diseases; (ii) under-
stand the scope and variation in outcomes reported and
how they are measured; and (iii) create a list of candi-
date core outcomes to inform the development of
pediatric COSs for MCAD deficiency and PKU [7]. We
hypothesized that our review would identify substantial
variation in the reporting of outcomes and outcome
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measurement instruments in the published MCAD defi-
ciency and PKU literature.
Materials and methods
Protocol and registration
The study protocol was developed in collaboration with
patient partners (MS, NP), registered in PROSPERO
(CRD42017073524), and published [17]. This review is
reported according to the Preferred Reporting Items for
Systematic Reviews and Meta-Analyses (PRISMA) guide-
lines (see Additional file 1) [18].
Search strategies and information sources
The study team developed separate search strategies to
identify publications related to MCAD deficiency and
PKU (further details, Additional file 1). Briefly, using the
OVID platform, we searched Ovid MEDLINE® and
Embase Classic+Embase. We also searched Cochrane
Library databases. Language and publication year filters
were applied to these searches to screen out non-English
language studies, for practical reasons, and studies pub-
lished before 1990 as the approach to diagnosing and
managing these diseases has changed over time. We fur-
ther searched the MEDLINE and EMBASE databases for
publications focusing on long-term follow-up initiatives
for the evaluation of newborn screening programs, as
MCAD deficiency and PKU are among the most com-
mon targets of such programs [19]. Because of the antic-
ipated low sensitivity of the database search for newborn
screening evaluation initiatives, we conducted supple-
mental citation and related articles searches using key
articles identified by the study team. Finally, we per-
formed a grey literature search to identify further articles
reporting or discussing outcomes for MCAD deficiency
or PKU, guided by the Grey Matters tool [20]. Due to re-
source constraints, we limited the time devoted to grey
literature searches to 15 h and prioritized sources that
the study team deemed most relevant (see Additional file
1). As a further step in the grey literature search, we
searched the COMET database [8] to identify COSs for
pediatric conditions other than PKU and MCAD
deficiency.
Eligibility criteria
We screened retrieved citations against a priori eligibility
criteria that were developed following the PICOS state-
ment (population, intervention, comparator, outcome,
study design). To be eligible for inclusion, articles had to
be focused on populations of children (aged 18 years or
younger) with MCAD deficiency or PKU. There were no
criteria specified for interventions or comparators. Arti-
cles had to be primary studies reporting on five or more
children; treatment guidelines or recommendations for
outcomes to be measured in future studies; or COS
studies (from the COMET database) for other pediatric
health conditions. The decision to restrict to primary
studies or recommendations was added post hoc to ex-
clude reviews of primary studies that would have already
been captured by our search strategy. We also made a
post hoc decision to include pediatric COS studies iden-
tified from the COMET database only if they included
potentially relevant outcomes not already captured from
other sources. All eligible articles had to report or dis-
cuss one or more outcomes in relation to pediatric PKU,
MCAD deficiency, and/or the long-term follow-up of
newborn screened diseases. We used a modified version
of the Outcome Measures in Rheumatology (OMER-
ACT) filter 2.0 definition to define an outcome as a re-
sult that is amenable to change due to the effects of a
health intervention [21]. We excluded citations that were
published abstracts only.
Study selection
We performed two levels of screening for all articles re-
trieved by our searches. For the peer-reviewed electronic
database searches, level one (title/abstract) screening was
conducted by two independent reviewers (among AR,
KT, MP). We used a liberal accelerated screening ap-
proach, whereby a single reviewer needed to classify a
citation as potentially eligible in order for it to advance
to the next level but two reviewers had to independently
exclude a citation in order for it to be removed. For the
supplemental long-term follow-up, grey literature, and
COMET database searches, a single author (MP) per-
formed level one screening. For all searches, level two
(full text) screening was conducted by two independent
reviewers (among AR, KT, MP), who were required to
fully agree on the inclusion or exclusion of an article;
conflicts were resolved by consensus discussion or with
a third team member.
Data extraction and synthesis
One reviewer extracted outcomes from eligible studies
into an electronic spreadsheet and a second reviewer
verified the extracted data. Data collection included in-
formation about study characteristics, outcome names
and definitions exactly as described by the study authors
for outcomes meeting the modified OMERACT defin-
ition as described above, and outcome measurement in-
struments when these were specified by the authors.
Through group discussion among a subset of study in-
vestigators with clinical and methodological expertise (JI,
PC, MTG, BKP), we combined and renamed outcomes
that were conceptually similar to arrive at a set of
‘unique’ outcomes [22]. Outcomes representing a sub-
concept of a broader outcome were kept separate when
the outcome was thought to be particularly clinically im-
portant and was also perceived as a plausible trial
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outcome that could be selected over the broader out-
come. Group discussion led to the creation of outcome
domains to further group related outcomes based on an
overarching concept (for example, physical growth and
anthropometry, child life impact, health services use and
costs) [7].
Assignment of outcomes to core areas
We mapped outcome domains onto one of five, mutually-
exclusive a priori defined core areas, four of which were
described in the OMERACT Filter 2.0 framework, a
literature-informed and consensus-developed process for
establishing core outcome sets endorsed by COMET:
death, life impact, pathophysiological manifestations, and
resource use [7, 21]. The fifth core area of growth and de-
velopment was included due to our focus on children, fol-
lowing the approach used in a previous pediatric COS
study [22]. Mapping of domains onto core areas was
achieved through group discussion and was based on the
alignment of the domain's overarching theme with the
description of the core areas from the original sources [21,
22]. The death core area covers general, disease-specific,
and intervention-specific causes of death. The life impact
core area includes quality of life, patient perceptions of
health, psychosocial impact, and secondary impacts on
caregivers. Resource use covers the direct and indirect
economic impact of the disease on an individual and
society. The pathophysiological manifestations core area
covers the physiological and biochemical impact of the
disease on the body’s organs and function, and also in-
cludes disease biomarkers [21]. The growth and develop-
ment core area incorporates outcomes measuring the
impact of the disease on the physical growth and cognitive
development of the child [22].
Results
Identification of studies
The initial MCAD deficiency, PKU, and newborn
screening long-term follow-up initiative database search
strategies identified 6072 citations (Fig. 1). From these,
566 studies were determined to be eligible for data ex-
traction. Due to time restraints and the large number of
studies that were eligible for PKU, we decided to limit
the initial data extraction for articles retrieved in the
PKU search to only those that were published in the year
2001 or more recently; we then reviewed outcomes from
studies from each previous year in turn, starting with
2000, until no new unique outcomes for PKU were iden-
tified. We initially extracted data from 308 eligible PKU-
relevant articles published between 2001 and 2017. A
review of an additional 16 PKU-relevant articles pub-
lished in 2000 did not identify any additional unique
outcomes so that PKU-relevant studies were excluded
when published before the year 2000 (see Additional file
2). Only one of the 18 eligible articles from the COMET
search reported a new relevant outcome that had not
been identified by studies from the other searches and
was retained for data synthesis. In total, 378 articles were
included in our review (see Additional file 3).
Outcomes for MCAD deficiency
Study characteristics
Our search strategies identified a total of 52 articles
relevant to MCAD deficiency: 35 MCAD deficiency
studies were identified from our disease-specific data-
base searches, 16 from newborn screening long-term
follow-up studies, and one from a previously published
pediatric COS. Most articles were published after 2009
(58%) and reported on observational studies (85%)
(Table 1). With respect to participant ages in primary
studies, the focus was commonly on newborns only
(45%) or children (40%), with a minority of studies
including children and adults. Articles reported or
discussed a median of four unique outcomes (range =
1–28) with most including five or fewer outcomes per
article (67%).
MCAD deficiency outcomes within domains and core areas
Data extraction initially yielded 230 MCAD deficiency
outcomes. The study team combined outcomes covering
similar concepts, yielding 83 unique MCAD deficiency
outcomes (Table 2). Unique outcomes were grouped
into 10 domains within the core areas. There was a rela-
tively even distribution of studies measuring outcomes
across the core areas for MCAD deficiency. The most
frequently reported and most diverse core area was
pathophysiological manifestations, which contained
three domains and 33 unique outcomes reported by 29/
52 articles (56%).
Death was the most commonly reported or discussed
unique outcome for MCAD deficiency (24/52 articles,
46%) (Table 2). The next most frequently reported
outcomes were cognition and intelligence/IQ,
hospitalization, metabolic decompensation, and overall
child development, which were each included in 14 arti-
cles (27% of articles). Among the other frequently re-
ported outcomes (reported in more than five studies),
four were in the pathophysiological manifestations core
area (three in the acute disease-specific manifestations
domain, one in the non disease-specific symptoms and
disorders domain), two were in the growth and develop-
ment core area (one in the cognition and development
domain, and one in the physical growth and anthropom-
etry domain), two in the resource use core area in the
health service use and costs domain, and one in the life
impact core area under the child and caregiver/family
life impact domain. One-third of the outcomes (27/83
outcomes) were reported by a single article.
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Changes over time to reported outcomes for MCAD
deficiency
We observed changes over time in the frequency of
reporting for some MCAD deficiency outcomes identi-
fied in our review (Table 2). For example, within the
growth and development domain, there was an increase
in reporting of outcomes in the physical growth and an-
thropometry domain: one of 17 articles (6%) published
between 2000 and 2009 reported outcomes within this
domain compared with 9 of 30 articles (30%) published
after 2009. There was a modest decrease in reporting of
outcomes in the cognition and development domain (8/
17 or 47% from 2000 to 2009 vs. 11/30 or 37% after
2009). There was also an increase in reporting of out-
comes in the life impact core area (6/17 or 35% from
2000 to 2009 vs. 16/30 or 53% after 2009) including the
outcome, overall clinician-assessed health status of child
(0/17 or 0% from 2000 to 2009 vs. 5/30 or 17% after
2009). Other changes included decreased reporting of
acute infections (4/17 or 24% from 2000 to 2009 vs. 3/30
or 10% after 2009) and acylcarnitines (3/17 from 2000 to
2009 or 18% vs. 0/30 or 0% after 2009).
Outcome measurement instruments for selected MCAD
deficiency outcomes
We summarized data for outcome measurement instru-
ments associated with neuro-psychological outcomes
and/or outcomes that were typically measured using
self- or parent-reported questionnaires. Among 25 arti-
cles measuring such outcomes for MCAD deficiency, we
identified 11 outcome measurement instruments associ-
ated with 11 unique outcomes (see Additional file 4).
The most diversely measured outcome was cognition
and intelligence/IQ: eight unique instruments were re-
ported by 14 articles, with the Wechsler Intelligence
Scales family of measurement instruments [23] being the
Fig. 1 Flow diagram of articles included in data synthesis
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most frequently specified (3/14 articles, 21%). The only
other outcome with more than one reported measure-
ment instrument was sensorimotor and motor function-
ing with four unique tools used in seven articles. One
measurement instrument was specified for each of care-
giver/family psychosocial well-being, behaviour problems
and externalizing mental health or behaviours disorders,
internalizing behaviour, and overall child development.
Studies reporting child quality of life, parental experi-
ences with illness care and prevention, attention-deficit
hyperactivity disorder (ADHD) or ADHD-like symp-
toms, autism spectrum disorder (ASD) or ASD-like
symptoms, and tic disorder were unclear about which
outcome measurement instruments were used. There
were not enough data available to assess any changes




PKU data synthesis included 343 articles consisting of
326 PKU-specific articles, 16 newborn screening long-
term follow-up studies, and one pediatric COS. Similar
to MCAD deficiency, over half of the articles included
for PKU data synthesis were published after 2009 (56%)
and mainly consisted of observational studies (83%)
(Table 1). A majority of articles were focused on chil-
dren (56%), with smaller proportions including children
and adults combined (32%) or newborns only (11%). A
number of studies clearly included children but did not
specify the age ranges of the included participants and,
as described for MCAD deficiency, further results were
not broken down by age group. Articles reported or
discussed a median of three unique outcomes (range =
1–25), with the majority including five or fewer out-
comes (76%).
PKU outcomes within domains and core areas
Data extraction initially yielded 565 outcomes. The study
team combined outcomes covering similar concepts into
97 unique PKU outcomes (Table 3). Unique outcomes
were grouped into 11 domains within the five core areas.
The most frequently represented core area was patho-
physiological manifestations, which contained two do-
mains and 31 unique outcomes reported by 281/343
articles (82%). The most diverse core area was life im-
pact with five domains and 44 unique outcomes re-
ported by 156/343 articles (45%).
Phenylalanine concentration in the blood and other tis-
sues was the most common unique outcome reported or
discussed among the articles included in our review (228/
343 articles, 66%). The next most frequently reported out-
comes were cognition and intelligence/IQ (82/343 articles,
24%) and metabolic syndrome/energy metabolism (52/343
Table 1 Characteristics of studies included in data synthesis
MCAD deficiency
(n = 52)
n (%) PKU (n = 343) n (%)
Publication Year
1994–1999 5 (10%) 2000–2004 84 (24%)
2000–2009 17 (33%) 2005–2009 67 (20%)
2010–2018 30 (58%) 2010–2014 120 (35%)
2015–2018 72 (21%)
Country of Origin
Australia 5 (10%) Australia 10 (3%)
Germany 7 (13%) Germany 37 (11%)
Iran 1 (2%) Iran 11 (3%)
Italy 0 (0%) Italy 25 (7%)
The Netherlands 5 (10%) The Netherlands 31 (9%)
Spain 3 (6%) Spain 26 (8%)
United Kingdom 5 (10%) United Kingdom 26 (8%)
United States 20 (38%) United States 68 (20%)
Other country 6 (12%) Other country 109 (32%)
Study Design






Observational study 44 (85%) Observational study 283 (83%)
Qualitative 1 (2%) Qualitative 2 (1%)
Trial 1 (2%) Trial 39 (11%)
Median (IQR)
Sample Size
n = 45a 59
(37–180)
n = 315c 54
(30–106)
Age Range of Study
Participants
n = 47b n = 325d
Newborns only 21 (45%) Newborns only 35 (11%)
Children 19 (40%) Infants 2 (1%)
Children and adults
combined
6 (13%) Children 181 (56%)
Children and maybe
adults









1 11 (21%) 1 83 (24%)
2–5 24 (46%) 2–5 180 (52%)
6–10 10 (19%) 6–10 51 (15%)
11 or more 7 (13%) 11 or more 29 (8%)
aExcluded five guidelines/recommendations that did not collect samples, one
study where the samples size was not clear, and one registered clinical trial
where only target sample size was reported
bExcluded five guidelines/recommendations that did not include participants
cExcluded 18 guidelines/recommendations which did not collect samples,
three studies where the samples size was not clear, and seven registered
clinical trials where only target sample size was reported
dExcluded 18 guidelines/recommendations which did not include participants
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Table 2 Unique MCAD deficiency outcomes reported in studies included for data synthesis
Outcome # (%) of articles
TOTAL (n = 52)
# (%) articles pre-
2000 (n = 5)
# (%) articles
2000–2009 (n = 17)
# (%) articles after
2009 (n = 30)
1. CORE AREA: GROWTH AND DEVELOPMENT 26 (50%) 4 (80%) 9 (53%) 13 (43%)
Domain: Physical Growth and Anthropometry 11 (21%) 1 (20%) 1 (6%) 9 (30%)
Body mass index 2 (4%) 0 (0%) 1 (6%) 1 (3%)
Growth 5 (10%) 1 (20%) 0 (0%) 4 (13%)
Head circumference 2 (4%) 0 (0%) 0 (0%) 2 (7%)
Height/length 4 (8%) 0 (0%) 1 (6%) 3 (10%)
Weight10* 6 (12%) 0 (0%) 1 (6%) 5 (17%)
Domain: Cognition and Development 23 (44%) 4 (80%) 8 (47%) 11 (37%)
Cognition and intelligence/IQ2* 14 (27%) 2 (40%) 4 (24%) 8 (27%)
Overall child development2* 14 (27%) 3 (60%) 5 (29%) 6 (20%)
Sensorimotor and motor functioning7* 7 (13%) 0 (0%) 2 (12%) 5 (17%)
Learning difficulties/disabilities 2 (4%) 0 (0%) 2 (12%) 0 (0%)
School function and placement 5 (10%) 0 (0%) 1 (6%) 4 (13%)
2. CORE AREA: LIFE IMPACT 25 (48%) 3 (60%) 6 (35%) 16 (53%)
Domain: Child and Caregiver/Family Life Impact 15 (29%) 1 (20%) 3 (18%) 11 (37%)
Child quality of life 1 (2%) 0 (0%) 0 (0%) 1 (3%)
Overall clinician-assessed health status of child10* 6 (12%) 1 (20%) 0 (0%) 5 (17%)
Caregiver/family psychosocial well-being 2 (4%) 0 (0%) 2 (12%) 0 (0%)
Parental experiences with illness care and prevention 1 (2%) 0 (0%) 0 (0%) 1 (3%)
Caregiver/family economic impact 3 (6%) 0 (0%) 1 (6%) 2 (7%)
Physical activity participation and tolerance 1 (2%) 0 (0%) 0 (0%) 1 (3%)
Achievement of treatment goals 1 (2%) 0 (0%) 0 (0%) 1 (3%)
Domain: Child Behaviour, Mental Health,
and Temperament
5 (10%) 2 (40%) 0 (0%) 3 (10%)
Behaviour problems and externalizing mental
health or behaviour disorders
4 (8%) 2 (40%) 0 (0%) 2 (7%)
Attention-deficit hyperactivity disorder (ADHD)
or ADHD-like symptoms
2 (4%) 1 (20%) 0 (0%) 1 (3%)
Internalizing mental health or mood disorders
and associated symptoms
1 (2%) 0 (0%) 0 (0%) 1 (3%)
Autism spectrum disorder (ASD) or ASD-like symptoms 1 (2%) 0 (0%) 0 (0%) 1 (3%)
Tic disorder 1 (2%) 0 (0%) 0 (0%) 1 (3%)
Domain: Disease Management and Feeding Behaviour 15 (29%) 2 (40%) 4 (24%) 9 (30%)
Age at treatment initiation 1 (2%) 0 (0%) 1 (6%) 0 (0%)
Possession or use of an emergency card or letter 1 (2%) 0 (0%) 1 (6%) 0 (0%)
Frequency of dietary analysis 1 (2%) 0 (0%) 0 (0%) 1 (3%)
Overall dietary intake relative to standards 1 (2%) 0 (0%) 0 (0%) 1 (3%)
Infant feeding difficulties 1 (2%) 0 (0%) 0 (0%) 1 (3%)
Feeding difficulties 2 (4%) 1 (20%) 0 (0%) 1 (3%)
Use of a feeding tube 3 (6%) 0 (0%) 1 (6%) 2 (7%)
Diet modification 3 (6%) 0 (0%) 1 (6%) 2 (7%)
Fasting 3 (6%) 1 (20%) 0 (0%) 2 (7%)
Fat restriction 1 (2%) 0 (0%) 1 (6%) 0 (0%)
Carnitine supplementation 5 (10%) 0 (0%) 2 (12%) 3 (10%)
Cornstarch supplementation 2 (4%) 0 (0%) 1 (6%) 1 (3%)
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Table 2 Unique MCAD deficiency outcomes reported in studies included for data synthesis (Continued)
Outcome # (%) of articles
TOTAL (n = 52)
# (%) articles pre-
2000 (n = 5)
# (%) articles
2000–2009 (n = 17)
# (%) articles after
2009 (n = 30)
Fatty acid supplementation 1 (2%) 0 (0%) 1 (6%) 0 (0%)
Vitamin supplementation 1 (2%) 0 (0%) 0 (0%) 1 (3%)
Prescription or use of medication, supplements,
medical foods other than carnitine, cornstarch,
or vitamins
2 (4%) 0 (0%) 0 (0%) 2 (7%)
Supplementation with rapidly available
carbohydrates during acute illness
2 (4%) 0 (0%) 2 (12%) 0 (0%)
Sick day plan 2 (4%) 0 (0%) 1 (6%) 1 (3%)
Prescription of use of medications or supplements
unrelated to MCAD deficiency
2 (4%) 1 (20%) 0 (0%) 1 (3%)
Adherence to prescribed or recommended
treatment or management strategy
2 (4%) 0 (0%) 1 (6%) 1 (3%)
3. CORE AREA: RESOURCE USE 18 (35%) 1 (20%) 7 (41%) 10 (33%)
Domain: Health Service Use and Costs 18 (35%) 1 (20%) 7 (41%) 10 (33%)
Access to care 2 (4%) 0 (0%) 0 (0%) 2 (7%)
Costs of care 2 (4%) 0 (0%) 1 (6%) 1 (3%)
Emergency department use10* 6 (12%) 0 (0%) 1 (6%) 5 (17%)
Hospitalization2* 14 (27%) 1 (20%) 5 (29%) 8 (27%)
Outpatient care use10* 6 (12%) 0 (0%) 2 (12%) 4 (13%)
Genetic counseling and family cascade carrier testing 4 (8%) 0 (0%) 0 (0%) 4 (13%)
Health education service use 1 (2%) 0 (0%) 0 (0%) 1 (3%)
Provision and coordination of services 1 (2%) 0 (0%) 1 (6%) 0 (0%)
4. CORE AREA: DEATH 24 (46%) 2 (40%) 9 (53%) 13 (43%)
Domain: Death 24 (46%) 2 (40%) 9 (53%) 13 (43%)
Death1 24 (46%) 2 (40%) 9 (53%) 13 (43%)
5. CORE AREA: PATHOPHYSIOLOGICAL MANIFESTATIONS 29 (56%) 5 (100%) 9 (53%) 15 (50%)
Domain: Acute Disease-specific Manifestations 22 (42%) 3 (60%) 7 (41%) 12 (40%)
Metabolic decompensation2* 14 (27%) 3 (60%) 4 (24%) 7 (23%)
Encephalopathy10* 6 (12%) 1 (20%) 3 (18%) 2 (7%)
Seizures7* 7 (13%) 2 (40%) 2 (12%) 3 (10%)
Cardiovascular symptoms and disorders 3 (6%) 0 (0%) 1 (6%) 2 (7%)
Respiratory symptoms and disorders 3 (6%) 0 (0%) 1 (6%) 2 (7%)
Muscle symptoms and disorders 4 (8%) 0 (0%) 1 (6%) 2 (7%)
Hypoglycaemia7* 7 (13%) 1 (20%) 3 (18%) 3 (10%)
Hyperammonemia 2 (4%) 0 (0%) 0 (0%) 2 (7%)
Hyperuricemia 1 (2%) 0 (0%) 0 (0%) 1 (3%)
Ketonuria 2 (4%) 0 (0%) 0 (0%) 2 (7%)
Metabolic acidosis 2 (4%) 0 (0%) 0 (0%) 2 (7%)
Psychogenic blindness 1 (2%) 1 (20%) 0 (0%) 0 (0%)
Chronic sequelae of an acute event 4 (8%) 3 (60%) 1 (6%) 0 (0%)
Domain: Non Disease-specific Symptoms and Disorders 13 (25%) 3 (60%) 5 (29%) 5 (17%)
Neurological symptoms and disorders 1 (2%) 0 (0%) 1 (6%) 0 (0%)
Signs of discomfort 1 (2%) 0 (0%) 0 (0%) 1 (3%)
Pallor 2 (4%) 0 (0%) 0 (0%) 2 (7%)
Dehydration 2 (4%) 0 (0%) 0 (0%) 2 (7%)
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articles, 15%). Among the 10 most frequently reported
unique outcomes, five were within the pathophysiological
manifestations core area (two in the monitoring of
disease-specific biomarkers and surrogate outcomes do-
main, three in the monitoring of non disease-specific bio-
markers and surrogate outcomes domain), four were
within the growth and development core area (three from
the physical growth and anthropometry domain, one from
cognition and development), and one from the life impact
core area (from the disease management and feeding be-
haviour domain). Sixteen percent of outcomes (16/97 out-
comes) were reported by a single study.
Changes over time to reported outcomes for PKU
We observed changes over time in the frequency of
reporting for some unique outcomes identified in the
reviewed studies related to PKU (Table 3). For example,
within the growth and development core area, there was
an increase in articles reporting unique outcomes in the
domain of physical growth and anthropometry from the
period between 2000 and 2004 (6/84 or 7% of articles)
to the period after 2014 (18/72 or 25% of articles).
Within this domain there was increased reporting of
body mass index (from 4/84 or 5% of articles from 2000
to 2004 to 14/72 or 19% of articles after 2014), and its
components, i.e., height/length (from 4/84 or 5% in
2000–2004 to 13/72 or 18% of articles after 2014), and
weight (from 2/84 or 2% of articles from 2000 to 2004 to
11/72 or 15% of articles after 2014). There was a
decrease in reporting of outcomes within the domain of
cognition and development (from 34/84 or 40% of arti-
cles from 2000 to 2004 to 19/72 or 26% of articles after
2014). The frequency of articles reporting outcomes in
the life impact core area increased over time (from 28/
84 or 33% of articles from 2000 to 2004 to 43/72 or 60%
of articles after 2014), with the largest increase seen in
the domain of disease management and feeding behav-
iour (from 19/84 or 23% of articles in 2000–2004 to 32/
72 or 44% of articles after 2014).
Outcome measurement instruments for selected PKU
outcomes
We summarized data for outcome measurement instru-
ments associated with neuro-psychological outcomes
and/or outcomes that were typically measured using
self- or parent-reported questionnaires. Among 131 arti-
cles that measured such outcomes for PKU, we identi-
fied 88 outcome measurement instruments associated
with 17 unique outcomes (see Additional file 5). The
three unique outcomes with the most diverse sets of in-
struments were in the cognition and development do-
main. For the outcome, cognition and intelligence/IQ,
there were 39 different instruments reported among 82
articles, with the Wechsler Intelligence Scales family of
measurement instruments [23] being the most fre-
quently specified (33/82 articles, 40%). Executive func-
tioning was measured using 25 different instruments
across 32 articles with the Behaviour Rating Inventory of
Table 2 Unique MCAD deficiency outcomes reported in studies included for data synthesis (Continued)
Outcome # (%) of articles
TOTAL (n = 52)
# (%) articles pre-
2000 (n = 5)
# (%) articles
2000–2009 (n = 17)
# (%) articles after
2009 (n = 30)
Acute infections6 10 (19%) 3 (60%) 4 (24%) 3 (10%)
Body temperature abnormalities 2 (4%) 0 (0%) 1 (6%) 1 (3%)
Gastrointestinal symptoms and disorders 3 (6%) 1 (20%) 1 (6%) 1 (3%)
Hyperglycaemia 1 (2%) 0 (0%) 0 (0%) 1 (3%)
Bronchospasms 1 (2%) 0 (0%) 0 (0%) 1 (3%)
Domain: Biomarkers of Nutritional and
Organ-specific Health
11 (21%) 1 (20%) 3 (18%) 7 (23%)
Acylcarnitines 3 (6%) 0 (0%) 3 (18%) 0 (0%)
Free carnitine 1 (2%) 0 (0%) 0 (0%) 1 (3%)
Total carnitine 5 (10%) 0 (0%) 2 (12%) 3 (10%)
Fasting tolerance biomarkers 1 (2%) 0 (0%) 0 (0%) 1 (3%)
Nutritional assessment biomarkers 5 (10%) 0 (0%) 2 (12%) 3 (10%)
Inflammation biomarkers 1 (2%) 0 (0%) 0 (0%) 1 (3%)
Liver health biomarkers 3 (6%) 0 (0%) 1 (6%) 2 (7%)
Kidney health biomarkers 2 (4%) 0 (0%) 0 (0%) 2 (7%)
Muscle health biomarkers 3 (6%) 1 (20%) 1 (6%) 1 (3%)
Neurological health biomarkers 1 (2%) 0 (0%) 0 (0%) 1 (3%)
General health biomarkers 2 (4%) 0 (0%) 0 (0%) 2 (7%)
1–10indicates top ten most reported or discussed unique outcomes, ties indicated with an asterisks
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Table 3 Unique PKU outcomes reported in studies included for data synthesis
Outcome # (%) of articles
TOTAL (n = 343)












1. CORE AREA: GROWTH AND DEVELOPMENT 153 (45%) 40 (48%) 28 (42%) 53 (44%) 32 (44%)
Domain: Physical Growth and Anthropometry 63 (18%) 6 (7%) 14 (21%) 25 (21%) 18 (25%)
Body mass index, overweight, or obesity status8* 35 (10%) 4 (5%) 3 (4%) 14 (12%) 14 (19%)
Growth 16 (5%) 1 (1%) 5 (7%) 8 (7%) 2 (3%)
Head circumference 8 (2%) 1 (1%) 1 (1%) 3 (3%) 3 (4%)
Height/length5* 42 (12%) 4 (5%) 7 (10%) 18 (15%) 13 (18%)
Weight 38 (11%) 2 (2%) 9 (13%) 16 (13%) 11 (15%)
Body composition 9 (3%) 1 (1%) 2 (3%) 4 (3%) 2 (3%)
Domain: Cognition and Development 110 (32%) 34 (40%) 19 (28%) 38 (32%) 19 (26%)
Cognition and intelligence/IQ2 82 (24%) 25 (30%) 14 (21%) 29 (24%) 14 (19%)
Overall child development 11 (3%) 3 (4%) 1 (1%) 5 (4%) 2 (3%)
Sensorimotor and motor functioning10* 32 (9%) 9 (11%) 4 (6%) 17 (14%) 2 (3%)
Learning difficulties/disabilities 1 (0%) 0 (0%) 1 (1%) 0 (0%) 0 (0%)
Academic achievement/school performance 20 (6%) 5 (6%) 1 (1%) 9 (8%) 5 (7%)
Executive functioning10* 32 (9%) 9 (11%) 5 (7%) 11 (9%) 7 (10%)
2. CORE AREA: LIFE IMPACT 156 (45%) 28 (33%) 24 (36%) 61 (51%) 43 (60%)
Domain: Child Life Impact 35 (10%) 4 (5%) 1 (1%) 20 (17%) 10 (14%)
Child quality of life 21 (6%) 2 (2%) 1 (1%) 12 (10%) 6 (8%)
Child psychosocial well-being and self-concept 15 (4%) 0 (0%) 0 (0%) 10 (8%) 5 (7%)
Child social impact and function 12 (3%) 2 (2%) 0 (0%) 6 (5%) 4 (6%)
Bodily pain or discomfort 7 (2%) 0 (0%) 0 (0%) 4 (3%) 3 (4%)
Sleep problems 1 (0%) 0 (0%) 0 (0%) 1 (1%) 0 (0%)
Overall clinician-assessed health status of child 4 (1%) 0 (0%) 0 (0%) 3 (3%) 1 (1%)
Child understanding of and self-efficacy with
management of PKU
3 (1%) 1 (1%) 0 (0%) 1 (1%) 1 (1%)
Achievement of treatment goals 1 (0%) 0 (0%) 0 (0%) 0 (0%) 1 (1%)
Domain: Caregiver/family Life Impact 19 (6%) 4 (5%) 1 (1%) 7 (6%) 7 (10%)
Impact of PKU on caregiver/family quality of life 10 (3%) 0 (0%) 0 (0%) 5 (4%) 5 (7%)
Caregiver/family psychosocial well-being 9 (3%) 4 (5%) 0 (0%) 2 (2%) 3 (4%)
Caregiver/family economic impact 5 (1%) 1 (1%) 1 (1%) 2 (2%) 1 (1%)
Impact of PKU on caregiver/family diet 1 (0%) 0 (0%) 0 (0%) 1 (1%) 0 (0%)
Domain: Child and Caregiver/family Life Impact 3 (1%) 1 (1%) 0 (0%) 0 (0%) 2 (3%)
Strategies used by parents to help children
cope with PKU
1 (0%) 0 (0%) 0 (0%) 0 (0%) 1 (1%)
Perceived control over behavior and skills 2 (1%) 1 (1%) 0 (0%) 0 (0%) 1 (1%)
Domain: Child Behaviour, Mental Health,
and Temperament
42 (12%) 8 (10%) 4 (6%) 19 (16%) 11 (15%)
Behaviour problems and externalizing mental
health or behaviour disorders
19 (6%) 5 (6%) 2 (3%) 8 (7%) 4 (6%)
Attention-deficit hyperactivity disorder (ADHD)
or ADHD-like symptoms
15 (4%) 2 (2%) 1 (1%) 8 (7%) 4 (6%)
Internalizing mental health or mood disorders
and associated symptoms
26 (8%) 4 (5%) 1 (1%) 15 (13%) 6 (8%)
Autism spectrum disorder (ASD) or ASD-like
symptoms
9 (3%) 0 (0%) 1 (1%) 5 (4%) 3 (4%)
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Table 3 Unique PKU outcomes reported in studies included for data synthesis (Continued)
Outcome # (%) of articles
TOTAL (n = 343)












Atypical behaviour and mental symptoms other
than those specified
1 (0%) 0 (0%) 0 (0%) 1 (1%) 0 (0%)
Temperament/personality 4 (1%) 1 (1%) 0 (0%) 3 (3%) 0 (0%)
Domain: Disease Management and Feeding
Behaviour
113 (33%) 19 (23%) 21 (31%) 41 (34%) 32 (44%)
Age at treatment initiation 4 (1%) 1 (1%) 0 (0%) 3 (3%) 0 (0%)
Infant breast and formula feeding 2 (1%) 0 (0%) 0 (0%) 1 (1%) 1 (1%)
Dietary intake of phenylalanine 28 (8%) 5 (6%) 5 (7%) 10 (8%) 8 (11%)
Dietary intake of amino acids other than
phenylalanine
6 (2%) 2 (2%) 0 (0%) 3 (3%) 1 (1%)
Dietary intake of medical foods or formula,
modified low-protein foods, and protein
substitutes
9 (3%) 2 (2%) 0 (0%) 6 (5%) 1 (1%)
Dietary intake of protein5* 42 (12%) 9 (11%) 5 (7%) 20 (17%) 8 (11%)
Dietary intake of energy 30 (9%) 8 (10%) 6 (9%) 11 (9%) 5 (7%)
Overall dietary intake relative to standards 5 (1%) 0 (0%) 0 (0%) 3 (3%) 2 (3%)
Dietary intake of fat 17 (5%) 5 (6%) 2 (3%) 6 (5%) 4 (6%)
Dietary intake of specific fatty acids 16 (5%) 6 (7%) 4 (6%) 4 (3%) 2 (3%)
Dietary intake of cholesterol 7 (2%) 3 (4%) 1 (1%) 3 (3%) 0 (0%)
Dietary intake of carbohydrates 15 (4%) 3 (4%) 3 (4%) 6 (5%) 3 (4%)
Dietary intake of fibre 7 (2%) 3 (4%) 1 (1%) 2 (2%) 1 (1%)
Glycemic index of foods consumed 1 (0%) 0 (0%) 0 (0%) 0 (0%) 1 (1%)
Dietary intake of vitamins and minerals 19 (6%) 6 (7%) 1 (1%) 6 (5%) 6 (8%)
Dietary intake of major food groups 4 (1%) 0 (0%) 0 (0%) 2 (2%) 2 (3%)
Eating behaviour 2 (1%) 0 (0%) 0 (0%) 1 (1%) 1 (1%)
Frequency of dietary analysis 1 (0%) 0 (0%) 0 (0%) 1 (1%) 0 (0%)
Adherence to PKU diet 27 (8%) 1 (1%) 7 (10%) 7 (6%) 12 (17%)
Prescriptions of use of medications to manage
PKU
1 (0%) 0 (0%) 0 (0%) 1 (1%) 0 (0%)
Phenylalanine tolerance 26 (8%) 1 (1%) 7 (10%) 7 (6%) 11 (15%)
Liberalization of PKU diet 3 (1%) 1 (1%) 0 (0%) 1 (1%) 1 (1%)
Child acceptability of PKU diet 14 (4%) 2 (2%) 1 (1%) 6 (5%) 5 (7%)
Caregiver/family acceptability of PKU diet 11 (3%) 0 (0%) 2 (3%) 7 (6%) 2 (3%)
3. CORE AREA: RESOURCE USE 11 (3%) 2 (2%) 1 (1%) 7 (6%) 1 (1%)
Domain: Health Service Use and Costs 11 (3%) 2 (2%) 1 (1%) 7 (6%) 1 (1%)
Access to care 1 (0%) 0 (0%) 0 (0%) 0 (0%) 1 (1%)
Costs of care 1 (0%) 0 (0%) 0 (0%) 1 (1%) 0 (0%)
Emergency department use 3 (1%) 0 (0%) 0 (0%) 3 (3%) 0 (0%)
Hospitalization 8 (2%) 2 (2%) 0 (0%) 6 (5%) 0 (0%)
Outpatient care use 5 (1%) 2 (2%) 0 (0%) 3 (3%) 0 (0%)
Genetic counseling and family cascade
carrier testing
4 (1%) 0 (0%) 0 (0%) 3 (3%) 1 (1%)
Health education service use 1 (0%) 0 (0%) 0 (0%) 1 (1%) 0 (0%)
Use of medical devices 3 (1%) 2 (2%) 0 (0%) 1 (1%) 0 (0%)
Provision and coordination of services 2 (1%) 1 (1%) 1 (1%) 0 (0%) 0 (0%)
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Table 3 Unique PKU outcomes reported in studies included for data synthesis (Continued)
Outcome # (%) of articles
TOTAL (n = 343)












4. CORE AREA: DEATH 9 (3%) 0 (0%) 1 (1%) 6 (5%) 2 (3%)
Domain: Death 9 (3%) 0 (0%) 1 (1%) 6 (5%) 2 (3%)
Death 9 (3%) 0 (0%) 1 (1%) 6 (5%) 2 (3%)
5. CORE AREA: PATHOPHYSIOLOGICAL
MANIFESTATIONS
281 (82%) 71 (85%) 53 (79%) 102 (85%) 55 (76%)
Domain: Monitoring of Disease-specific
Biomarkers and Surrogate Outcomes
234 (68%) 57 (68%) 42 (63%) 86 (72%) 49 (68%)
Frequency of phenylalanine or tyrosine
monitoring
9 (3%) 2 (2%) 0 (0%) 6 (5%) 1 (1%)
Phenylalanine concentration in the blood
and other tissues1
228 (66%) 56 (67%) 41 (61%) 83 (69%) 48 (67%)
Tyrosine concentration in the blood7 39 (11%) 9 (11%) 5 (7%) 18 (15%) 7 (10%)
Phenylalanine to tyrosine ratio 13 (4%) 1 (1%) 2 (3%) 7 (6%) 3 (4%)
Phenylalanine metabolism and kinetics 4 (1%) 2 (2%) 0 (0%) 1 (1%) 1 (1%)
Large neutral amino acid (LNAA) concentration
in the blood
1 (0%) 0 (0%) 0 (0%) 1 (1%) 0 (0%)
Micronutrient deficiency 2 (1%) 0 (0%) 0 (0%) 0 (0%) 2 (3%)
BH4 malabsorption 1 (0%) 0 (0%) 1 (1%) 0 (0%) 0 (0%)
Pharmacokinetics of sapropterin 2 (1%) 0 (0%) 1 (1%) 0 (0%) 1 (1%)
Domain: Monitoring of Non Disease-Specific
Biomarkers and Surrogate Outcomes
151 (44%) 37 (44%) 28 (42%) 55 (46%) 31 (43%)
Bone health 29 (8%) 4 (5%) 3 (4%) 14 (12%) 8 (11%)
Blood health 27 (8%) 4 (5%) 3 (4%) 13 (11%) 7 (10%)
Neurological health – Clinical symptoms and
diagnoses
20 (6%) 3 (4%) 4 (6%) 9 (8%) 4 (6%)
Neurological health – Biomarkers and
surrogate outcomes8*
35 (10%) 12 (14%) 5 (7%) 12 (10%) 6 (8%)
Neurotransmitters 7 (2%) 3 (4%) 2 (3%) 1 (1%) 1 (1%)
Liver health 6 (2%) 0 (0%) 0 (0%) 4 (3%) 2 (3%)
Kidney health 9 (3%) 2 (2%) 0 (0%) 4 (3%) 3 (4%)
Metabolic syndrome/energy metabolism3 52 (15%) 12 (14%) 10 (15%) 20 (17%) 10 (14%)
Biomarkers of protein synthesis 22 (6%) 3 (4%) 4 (6%) 11 (9%) 4 (6%)
Biomarkers of vitamins and trace minerals4 45 (13%) 9 (11%) 5 (7%) 19 (16%) 12 (17%)
Concentration of amino acids other than
Phe/Tyr in the blood
28 (8%) 4 (5%) 3 (4%) 12 (10%) 9 (13%)
Biomarkers of antioxidant status, oxidative
stress and inflammation
20 (6%) 4 (5%) 7 (10%) 6 (5%) 3 (4%)
Neonatal complications 2 (1%) 0 (0%) 0 (0%) 1 (1%) 1 (1%)
Dermatological health 6 (2%) 0 (0%) 1 (1%) 1 (1%) 4 (6%)
Gastrointestinal health 8 (2%) 0 (0%) 0 (0%) 4 (3%) 4 (6%)
Immune system disorders 1 (0%) 0 (0%) 0 (0%) 0 (0%) 1 (1%)
Infections 4 (1%) 0 (0%) 0 (0%) 1 (1%) 3 (4%)
Musculoskeletal health 9 (3%) 0 (0%) 0 (0%) 7 (6%) 2 (3%)
Respiratory health 5 (1%) 0 (0%) 0 (0%) 2 (2%) 3 (4%)
Dental and oral health 3 (1%) 1 (1%) 0 (0%) 1 (1%) 1 (1%)
Ear health 1 (0%) 0 (0%) 0 (0%) 0 (0%) 1 (1%)
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Executive Function (BRIEF) [24] being the most fre-
quently specified (10/32 articles, 31%). For sensorimotor
and motor functioning, there were 17 different instru-
ments across 32 articles with the Bayley Scales of Infant
and Toddler Development [25] being the most fre-
quently reported (4/32 articles, 13%). There were no
notable trends in the reporting of outcome measurement
instruments over time.
Discussion
We reviewed pediatric literature related to MCAD defi-
ciency and PKU to identify the scope of reported and
recommended outcomes. Similar to reviews of outcomes
reporting in other clinical areas [26–28], we found sub-
stantial diversity of outcomes reported across the five
core areas of outcome measurement for both diseases.
Notably, almost a third of outcomes for MCAD defi-
ciency and over 15% for PKU were reported in only a
single study. With little overlap of outcomes across stud-
ies, this suggests limited potential for combining or
comparing results across published studies for these dis-
eases and highlights the potential value of developing
COSs for MCAD deficiency and PKU.
For MCAD deficiency, there was relatively equal
representation of each of the five core areas: approxi-
mately half of published studies (46–56%) incorporated
outcomes within each core area with the exception of re-
source use (35%). The most frequently reported out-
comes for MCAD deficiency were focused on the risk of
life-threatening consequences and manifestations of the
disease. This emphasis on mortality-related outcomes is
seen in COSs for other potentially life-threatening con-
ditions like post-partum haemorrhage [29] and fetal
growth restriction [30]. By contrast, for PKU, there was
a dominance of the pathophysiological manifestations
core area, similar to that seen in a review of outcomes
for type II diabetes [28], and for children with feeding
tubes and neurological impairments [22]. The focus on
pathophysiological manifestations for PKU reflects fre-
quent reporting of the specific outcome blood phenyl-
alanine concentration. Blood phenylalanine is a well-
established surrogate indicator of clinical symptoms for
PKU and has been used as a marker of treatment adher-
ence in treatment guidelines and as a clinical trial out-
come [13–15]. Industry-sponsored studies may also be
more likely to incorporate short-term and surrogate out-
comes in evaluating treatments for rare diseases [4],
which could contribute to the prominence of patho-
physiological end-points in studies of PKU. However,
the relatively small number of articles on PKU that re-
ported patient-oriented outcomes (as compared with
blood phenylalanine) is potentially of concern.
Specifically, patient-oriented outcomes that reflect the
lived experience of patients and their caregivers have
emerged as a key priority for evaluative studies in the
field of rare diseases [4]. The life impact core area, which
covers many such outcomes, appeared relatively well-
represented in articles reporting on MCAD deficiency,
although most individual outcomes within this core area
were themselves reported only once or twice, perhaps
reflecting a lack of consensus on which aspects of life
impacts are of highest priority for measurement. In the
PKU literature, the life impact core area was less com-
monly represented but, similar to MCAD deficiency, it
was by far the most diverse core area, with 44 unique
outcomes. This suggests a need to work directly with
patients and their family members to identify which
patient-oriented outcomes are most meaningful to
measure in future research for both diseases. Further-
more, there was diversity in the specific outcome
measurement instruments reported for many of the
patient- or caregiver-reported outcomes for both dis-
eases. There are very few disease-specific question-
naires for MCAD deficiency and PKU, likely because
the small patient populations make the development
and validation of such outcome measurement instru-
ments challenging [6]. Thus, in addition to under-
standing which outcomes are most highly prioritized,
there is a need to select the generic instruments (or
develop disease-specific instruments) that best capture
the life impact of MCAD deficiency and PKU for pa-
tients and their families.
This review has several strengths. The study followed
a published protocol written in collaboration with pa-
tient partners, and established methodology as reported
in the PRISMA statement and COMET handbook [7,
18]. Our search for relevant articles was extensive, cov-
ering electronic databases of peer reviewed literature,
supplemented by a grey literature search guided by Grey
Matters [20], additional search strategies for long-term
follow-up initiatives of newborn screening, and a search
of the COMET database for pediatric COSs [8]. Through
data extraction and synthesis we created a comprehen-
sive list of all of the outcomes reported or recommended
Table 3 Unique PKU outcomes reported in studies included for data synthesis (Continued)
Outcome # (%) of articles
TOTAL (n = 343)












Eye health 2 (1%) 0 (0%) 0 (0%) 1 (1%) 1 (1%)
1–10indicates top ten most reported or discussed unique outcomes, ties indicated with an asterisks; p indicates neuro-psychological outcomes
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in the MCAD deficiency and PKU literature that can be
used to support the development of COSs for these dis-
eases. Our review also has limitations. Despite our com-
prehensive search strategy, the non-specific nature of
index terms for newborn screening long-term follow-up
initiatives made searching for studies in that area chal-
lenging and we may have missed relevant published arti-
cles. Due to the size of the PKU literature we opted to
extract literature from the year 2000 onward and we
may have missed unique outcomes that were reported
only before that date. We only included studies
published in English for practical reasons and may have
missed important literature published in other lan-
guages. We also originally planned to summarize
outcomes by the age of the children studied and we con-
sidered a summary that accounted for disease severity,
but we were unable to extract these variables consist-
ently due to incomplete reporting of sample characteris-
tics. Similarly, we did not report outcomes by other
study characteristics such as follow-up time for longitu-
dinal studies and we did not collect information about
how often outcomes were collected in studies where re-
peat measurements would have been possible.
Our findings suggest that evaluative studies of inter-
ventions for MCAD deficiency and PKU would benefit
from COSs given the multitude of outcomes in the lit-
erature. The 83 MCAD deficiency and 97 PKU out-
comes that we identified constitute a list of candidate
core outcomes for the next stage of COS development,
which involves a consensus process to narrow down the
list to a small number of outcomes that are of highest
priority for collection in future studies [7]. In order to
make final recommendations about outcomes and also
outcome measurement tools, the consensus process
must involve multiple stakeholders, including patients
and family members, to ensure that future evaluative re-
search is patient-oriented and focused on meaningful
outcomes. This is particularly important given the large
number of outcomes and outcome measurement instru-
ments that we identified in the life impact core area for
both diseases, and the focus on pathophysiological rather
than patient-oriented outcomes in the PKU literature.
Conclusions
Substantial heterogeneity exists in the outcomes re-
ported in the MCAD deficiency and PKU literature and
a diversity of outcome measurement instruments was
used to measure many of these outcomes. This lack of
consistency impedes comparisons among studies and
limits the potential for data synthesis, leading to ineffi-
cient use of limited resources available for evaluating the
effectiveness of new and existing interventions. Our
findings suggest that future studies of the effectiveness
and comparative effectiveness of interventions for
pediatric MCAD deficiency and PKU would benefit from
disease-specific COSs.
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